alexchew的个人主页 - 老虎社区

alexchew

alexchew

暂无个人介绍

IP属地：未知

4关注

0粉丝

1主题

0勋章

2021-10-21

Share

@小虎活动:【晒单有奖】晒晒我最赚钱的股票？

2021-09-28

Novavax will win in children market for sure

Novavax Is a Short-Term Trade in a Long-Term Paradigm

2021-03-15

gd

AT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576481856577453","uuid":"3576481856577453","gmtCreate":1613387833323,"gmtModify":1628736347160,"name":"alexchew","pinyin":"alexchew","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":853184285,"gmtCreate":1634780125646,"gmtModify":1634780125764,"author":{"id":"3576481856577453","authorId":"3576481856577453","name":"alexchew","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576481856577453","authorIdStr":"3576481856577453"},"themes":[],"htmlText":"Share","listText":"Share","text":"Share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853184285","repostId":"859078451","repostType":1,"repost":{"id":859078451,"gmtCreate":1634645947869,"gmtModify":1744960744780,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"【晒单有奖】晒晒我最赚钱的股票？","htmlText":"你晒单，我免单，即日起至下周一，凡是参与晒单的虎友们都有机会获得免佣卡、笔记本、虎币等多种好礼。最近股市又双叒叕涨了！港股今日高开高走，尾盘进一步扩大，恒指收涨25787点，涨幅达1.49%。科技股再度暴动，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨10%，<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a> 涨超5%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a>、 <a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 皆上杨。 美股纳斯达克指数与标普500指数均录的连续四个交易日上涨，因好于预期的业绩和经济数据缓解了对经济前景的担忧。科技股<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/MSFT\">$微软(MSFT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a> 纷纷冲击新高，中概股","listText":"你晒单，我免单，即日起至下周一，凡是参与晒单的虎友们都有机会获得免佣卡、笔记本、虎币等多种好礼。最近股市又双叒叕涨了！港股今日高开高走，尾盘进一步扩大，恒指收涨25787点，涨幅达1.49%。科技股再度暴动，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨10%，<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a> 涨超5%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a>、 <a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 皆上杨。 美股纳斯达克指数与标普500指数均录的连续四个交易日上涨，因好于预期的业绩和经济数据缓解了对经济前景的担忧。科技股<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/MSFT\">$微软(MSFT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a> 纷纷冲击新高，中概股","text":"你晒单，我免单，即日起至下周一，凡是参与晒单的虎友们都有机会获得免佣卡、笔记本、虎币等多种好礼。最近股市又双叒叕涨了！港股今日高开高走，尾盘进一步扩大，恒指收涨25787点，涨幅达1.49%。科技股再度暴动，$快手-W(01024)$ 大涨10%，$小米集团-W(01810)$ 涨超5%，$阿里巴巴-SW(09988)$、 $美团-W(03690)$ 、$腾讯控股(00700)$ 皆上杨。 美股纳斯达克指数与标普500指数均录的连续四个交易日上涨，因好于预期的业绩和经济数据缓解了对经济前景的担忧。科技股$特斯拉(TSLA)$ 、$微软(MSFT)$ $苹果(AAPL)$ 纷纷冲击新高，中概股","images":[{"img":"https://static.tigerbbs.com/56d1d61084247d955b3196f8e9717aa0","width":"1784","height":"1088"},{"img":"https://static.tigerbbs.com/42eafb9578606069d6fbd6d02894dae5","width":"1000","height":"1000"},{"img":"https://static.tigerbbs.com/6f30f55876f2beb2be0d910d8b0f5ab2","width":"225","height":"225"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859078451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862065262,"gmtCreate":1632819141223,"gmtModify":1632819141327,"author":{"id":"3576481856577453","authorId":"3576481856577453","name":"alexchew","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576481856577453","authorIdStr":"3576481856577453"},"themes":[],"htmlText":"Novavax will win in children market for sure","listText":"Novavax will win in children market for sure","text":"Novavax will win in children market for sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862065262","repostId":"1198320620","repostType":2,"repost":{"id":"1198320620","kind":"news","pubTimestamp":1632482340,"share":"https://www.laohu8.com/m/news/1198320620?lang=&edition=full","pubTime":"2021-09-24 19:19","market":"us","language":"en","title":"Novavax Is a Short-Term Trade in a Long-Term Paradigm","url":"https://stock-news.laohu8.com/highlight/detail?id=1198320620","media":"InvestorPlace","summary":"The tech underlining NVAX stock isn't fast enough to provide a first-response solution.\n\nI’ve said t","content":"<blockquote>\n <b>The tech underlining NVAX stock isn't fast enough to provide a first-response solution.</b>\n</blockquote>\n<p>I’ve said this before and I’ll say it again: without any hesitation,&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stock is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest beneficiaries of the new normal.</p>\n<p>As the&nbsp;<i><a href=\"https://laohu8.com/S/NYT\">New York Times</a></i>&nbsp;reported last year, NVAX stock was essentially “on the verge of collapse.” The underlying company had researched and developed several vaccines, only to fail clinically.</p>\n<p>This time, though, things are different. What’s usually a phrase reserved for scorn turned out to be true in a very positive framework.</p>\n<p>Thanks to a pivotal investment in Novavax by the former Trump administration, the biotechnology firm got the lifeline it desperately needed. From a share price that was flirting with the dollar menu, NVAX stock eventually soared to its current triple-digit offering.</p>\n<p>Of course, with such a dramatic turnaround, it raises the question: can those eyeballing Novavax today count on a profitable decision?</p>\n<p>Although it’s late in the game regarding the vaccination race against the novel coronavirus, NVAX stock has the right stuff to swing northbound — at least on a near-term basis.</p>\n<p>As our own Joseph Nograles stated, Novavax “scored a major victorywhen the European Union (EU)&nbsp;inked a supply contract&nbsp;with the pharmaceutical firm for up to 200 million doses.”</p>\n<p>Initially, as Nograles noted, the purchase seems a strange one.</p>\n<p>“After all, the vast majority of EU countries already have at least 60% to 70% of their populations fully vaccinated,” he wrote.</p>\n<p>However, the Europeans are thinking long term.</p>\n<p>“[T]he answer lies in the EU’s strategy to defend itself against future variants — as well as to prepare for possible booster shots,” Nograles wrote.</p>\n<p>So yes, Novavax has upside potential but for how long?</p>\n<p><b>Long-Term Dynamics Don’t Support NVAX Stock</b></p>\n<p>Per my colleague’s analysis, the EU is implementing a cohesive, broad-based strategy.</p>\n<p>“Novavax’s vaccine is unique in that it uses alternative technology to what’s currently in the market. Rather than being mRNA-based, it’s a&nbsp;subunit protein vaccine. As such, it’s similar to an mRNA-based shot, but a key difference is that its coronavirus spike protein is already part of the dose. Plus, Novavax’s vaccine has an adjuvant made from tree bark that helps improve a patient’s immune response.”</p>\n<p>While the subunit approach (which is a proven one used todevelop the hepatis B vaccine) is an attractive case for NVAX stock, it has certain weaknesses.</p>\n<p>Yes, the established track record will help ease concerns for those who are on the fence regarding inoculation against Covid-19. But at the same time, subunits are more expensive and possibly more time-intensive to develop.</p>\n<p>According to information from Gavi.org, subunit vaccines use living bacteria, yeast and other living organisms that need more time and specific conditions do grow. This makes themmore expensive.</p>\n<p>Further, the complexity behind subunit vaccines may have contributed to Novavax’s solution falling behind its rivals, mainly<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>&nbsp;(NYSE:<b><u>PFE</u></b>)and<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>), which used the mRNA approach.</p>\n<p>Again, in the near term, NVAX stock offers a strong narrative, but on a longer-term basis, the subunit may prove less effective.</p>\n<p>As an article on Statnews.com declared, weneed to start preparing now for the next pandemic. Even then, there’s not a whole lot that can be done about virus outbreaks given our globalized transportation networks. Therefore, a quick, efficient response — as in mRNA vaccines — is key.</p>\n<p><b>Being Realistic About the Circumstances</b></p>\n<p>I sincerely hope that no one interprets the above as me being negative toward NVAX stock. Last year, I was very hopeful that Novavax would be the first one across the clinical finish line. Again, as a proven platform, a subunit-based Covid-19 vaccine offers massive potential.</p>\n<p>However, it wasn’t to be. The superior manufacturing profile of mRNA vaccines won out.</p>\n<p>While subunits may prove to be more effective over the long haul, the Covid pandemic proved that response speed is the priority. Like it or not, that favors nucleic-acid-based approaches.</p>\n<p>That’s not to say that NVAX stock is due for the dumpsters. In the short run, there could be some upside here. However, I wouldn’t bet the house on Novavax unless the underlying science and economics of scaled-up production somehow changes.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Is a Short-Term Trade in a Long-Term Paradigm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Is a Short-Term Trade in a Long-Term Paradigm\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 19:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/nvax-stock-short-term-trade-in-long-term-paradigm/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The tech underlining NVAX stock isn't fast enough to provide a first-response solution.\n\nI’ve said this before and I’ll say it again: without any hesitation, Novavax stock is one of the biggest ...</p>\n\n<a href=\"https://investorplace.com/2021/09/nvax-stock-short-term-trade-in-long-term-paradigm/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/09/nvax-stock-short-term-trade-in-long-term-paradigm/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198320620","content_text":"The tech underlining NVAX stock isn't fast enough to provide a first-response solution.\n\nI’ve said this before and I’ll say it again: without any hesitation, Novavax stock is one of the biggest beneficiaries of the new normal.\nAs the New York Times reported last year, NVAX stock was essentially “on the verge of collapse.” The underlying company had researched and developed several vaccines, only to fail clinically.\nThis time, though, things are different. What’s usually a phrase reserved for scorn turned out to be true in a very positive framework.\nThanks to a pivotal investment in Novavax by the former Trump administration, the biotechnology firm got the lifeline it desperately needed. From a share price that was flirting with the dollar menu, NVAX stock eventually soared to its current triple-digit offering.\nOf course, with such a dramatic turnaround, it raises the question: can those eyeballing Novavax today count on a profitable decision?\nAlthough it’s late in the game regarding the vaccination race against the novel coronavirus, NVAX stock has the right stuff to swing northbound — at least on a near-term basis.\nAs our own Joseph Nograles stated, Novavax “scored a major victorywhen the European Union (EU) inked a supply contract with the pharmaceutical firm for up to 200 million doses.”\nInitially, as Nograles noted, the purchase seems a strange one.\n“After all, the vast majority of EU countries already have at least 60% to 70% of their populations fully vaccinated,” he wrote.\nHowever, the Europeans are thinking long term.\n“[T]he answer lies in the EU’s strategy to defend itself against future variants — as well as to prepare for possible booster shots,” Nograles wrote.\nSo yes, Novavax has upside potential but for how long?\nLong-Term Dynamics Don’t Support NVAX Stock\nPer my colleague’s analysis, the EU is implementing a cohesive, broad-based strategy.\n“Novavax’s vaccine is unique in that it uses alternative technology to what’s currently in the market. Rather than being mRNA-based, it’s a subunit protein vaccine. As such, it’s similar to an mRNA-based shot, but a key difference is that its coronavirus spike protein is already part of the dose. Plus, Novavax’s vaccine has an adjuvant made from tree bark that helps improve a patient’s immune response.”\nWhile the subunit approach (which is a proven one used todevelop the hepatis B vaccine) is an attractive case for NVAX stock, it has certain weaknesses.\nYes, the established track record will help ease concerns for those who are on the fence regarding inoculation against Covid-19. But at the same time, subunits are more expensive and possibly more time-intensive to develop.\nAccording to information from Gavi.org, subunit vaccines use living bacteria, yeast and other living organisms that need more time and specific conditions do grow. This makes themmore expensive.\nFurther, the complexity behind subunit vaccines may have contributed to Novavax’s solution falling behind its rivals, mainlyPfizer (NYSE:PFE)andModerna(NASDAQ:MRNA), which used the mRNA approach.\nAgain, in the near term, NVAX stock offers a strong narrative, but on a longer-term basis, the subunit may prove less effective.\nAs an article on Statnews.com declared, weneed to start preparing now for the next pandemic. Even then, there’s not a whole lot that can be done about virus outbreaks given our globalized transportation networks. Therefore, a quick, efficient response — as in mRNA vaccines — is key.\nBeing Realistic About the Circumstances\nI sincerely hope that no one interprets the above as me being negative toward NVAX stock. Last year, I was very hopeful that Novavax would be the first one across the clinical finish line. Again, as a proven platform, a subunit-based Covid-19 vaccine offers massive potential.\nHowever, it wasn’t to be. The superior manufacturing profile of mRNA vaccines won out.\nWhile subunits may prove to be more effective over the long haul, the Covid pandemic proved that response speed is the priority. Like it or not, that favors nucleic-acid-based approaches.\nThat’s not to say that NVAX stock is due for the dumpsters. In the short run, there could be some upside here. However, I wouldn’t bet the house on Novavax unless the underlying science and economics of scaled-up production somehow changes.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":322062036,"gmtCreate":1615738006525,"gmtModify":1703492485850,"author":{"id":"3576481856577453","authorId":"3576481856577453","name":"alexchew","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576481856577453","authorIdStr":"3576481856577453"},"themes":[],"htmlText":"gd","listText":"gd","text":"gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/322062036","repostId":"1114441743","repostType":4,"repost":{"id":"1114441743","kind":"news","pubTimestamp":1615562490,"share":"https://www.laohu8.com/m/news/1114441743?lang=&edition=full","pubTime":"2021-03-12 23:21","market":"us","language":"en","title":"AT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1114441743","media":"cnbc","summary":"KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for H","content":"<div>\n<p>KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 ...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-12 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 ...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"At&T"},"source_url":"https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1114441743","content_text":"KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 million U.S. subscribers by 2025.\nHBO Max is expected to expand to around 60 markets outside the U.S. this year and will launch a lower-cost version with advertising in June.\n\nAT&T increased its subscriber forecast for HBO Max and HBO on Friday.\nThe telecommunications company, which owns WarnerMedia, said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 million U.S. subscribers by 2025, a relatively low bar considering the premium cable channel HBO already had around 33 million subscribers ahead of the HBO Max’s launch.\nThe company also expects to see between 67 million and 70 million HBO Max subscribers worldwide by the end of 2021. AT&T had previously set a forecast of between 75 million and 90 million subscribers globally by 2025.\nHBO Max is expected to expand to around 60 markets outside the U.S. this year and will launch a lower-cost version with advertising in June.\nIn January, WarnerMedia, reported that HBO and HBO Max had a combined 41.5 million domestic subscribers, up 20% from 34.6 million a year prior.\nOf the 37.7 million HBO Max-eligible subscribers, 30 million came from wholesalers and 6.8 million were through retail channels. Retail subscribers are those that purchase the streaming service directly, not through a cable subscription or other streaming subscription.\nThis means that nearly half of HBO subscribers who were eligible to get HBO Max have not signed up yet.\nAT&T’s new forecast comes as Netflix recently surpassed 200 million subscribersduring the fourth quarter 2020, and and Disney’s streaming service Disney+ surpassed 100 million subscribers just 16 months after its launch.","news_type":1,"symbols_score_info":{"T":0.9}},"isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":322062036,"gmtCreate":1615738006525,"gmtModify":1703492485850,"author":{"id":"3576481856577453","authorId":"3576481856577453","name":"alexchew","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576481856577453","authorIdStr":"3576481856577453"},"themes":[],"htmlText":"gd","listText":"gd","text":"gd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/322062036","repostId":"1114441743","repostType":4,"repost":{"id":"1114441743","kind":"news","pubTimestamp":1615562490,"share":"https://www.laohu8.com/m/news/1114441743?lang=&edition=full","pubTime":"2021-03-12 23:21","market":"us","language":"en","title":"AT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1114441743","media":"cnbc","summary":"KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for H","content":"<div>\n<p>KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 ...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAT&T raises HBO Max subscriber forecast, sees 120 million to 150 million by the end of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-12 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 ...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"At&T"},"source_url":"https://www.cnbc.com/2021/03/12/att-expects-120-million-to-150-million-hbo-max-subs-by-end-of-2025.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1114441743","content_text":"KEY POINTS\n\nAT&T said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 million U.S. subscribers by 2025.\nHBO Max is expected to expand to around 60 markets outside the U.S. this year and will launch a lower-cost version with advertising in June.\n\nAT&T increased its subscriber forecast for HBO Max and HBO on Friday.\nThe telecommunications company, which owns WarnerMedia, said it now expects global subscribers of between 120 million and 150 million for HBO Max and HBO by the end of 2025.\nBack in October 2019, the company set a goal of hitting 50 million U.S. subscribers by 2025, a relatively low bar considering the premium cable channel HBO already had around 33 million subscribers ahead of the HBO Max’s launch.\nThe company also expects to see between 67 million and 70 million HBO Max subscribers worldwide by the end of 2021. AT&T had previously set a forecast of between 75 million and 90 million subscribers globally by 2025.\nHBO Max is expected to expand to around 60 markets outside the U.S. this year and will launch a lower-cost version with advertising in June.\nIn January, WarnerMedia, reported that HBO and HBO Max had a combined 41.5 million domestic subscribers, up 20% from 34.6 million a year prior.\nOf the 37.7 million HBO Max-eligible subscribers, 30 million came from wholesalers and 6.8 million were through retail channels. Retail subscribers are those that purchase the streaming service directly, not through a cable subscription or other streaming subscription.\nThis means that nearly half of HBO subscribers who were eligible to get HBO Max have not signed up yet.\nAT&T’s new forecast comes as Netflix recently surpassed 200 million subscribersduring the fourth quarter 2020, and and Disney’s streaming service Disney+ surpassed 100 million subscribers just 16 months after its launch.","news_type":1,"symbols_score_info":{"T":0.9}},"isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":853184285,"gmtCreate":1634780125646,"gmtModify":1634780125764,"author":{"id":"3576481856577453","authorId":"3576481856577453","name":"alexchew","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576481856577453","authorIdStr":"3576481856577453"},"themes":[],"htmlText":"Share","listText":"Share","text":"Share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853184285","repostId":"859078451","repostType":1,"repost":{"id":859078451,"gmtCreate":1634645947869,"gmtModify":1744960744780,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"【晒单有奖】晒晒我最赚钱的股票？","htmlText":"你晒单，我免单，即日起至下周一，凡是参与晒单的虎友们都有机会获得免佣卡、笔记本、虎币等多种好礼。最近股市又双叒叕涨了！港股今日高开高走，尾盘进一步扩大，恒指收涨25787点，涨幅达1.49%。科技股再度暴动，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨10%，<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a> 涨超5%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a>、 <a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 皆上杨。 美股纳斯达克指数与标普500指数均录的连续四个交易日上涨，因好于预期的业绩和经济数据缓解了对经济前景的担忧。科技股<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/MSFT\">$微软(MSFT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a> 纷纷冲击新高，中概股","listText":"你晒单，我免单，即日起至下周一，凡是参与晒单的虎友们都有机会获得免佣卡、笔记本、虎币等多种好礼。最近股市又双叒叕涨了！港股今日高开高走，尾盘进一步扩大，恒指收涨25787点，涨幅达1.49%。科技股再度暴动，<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 大涨10%，<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a> 涨超5%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a>、 <a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 皆上杨。 美股纳斯达克指数与标普500指数均录的连续四个交易日上涨，因好于预期的业绩和经济数据缓解了对经济前景的担忧。科技股<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/MSFT\">$微软(MSFT)$</a> <a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a> 纷纷冲击新高，中概股","text":"你晒单，我免单，即日起至下周一，凡是参与晒单的虎友们都有机会获得免佣卡、笔记本、虎币等多种好礼。最近股市又双叒叕涨了！港股今日高开高走，尾盘进一步扩大，恒指收涨25787点，涨幅达1.49%。科技股再度暴动，$快手-W(01024)$ 大涨10%，$小米集团-W(01810)$ 涨超5%，$阿里巴巴-SW(09988)$、 $美团-W(03690)$ 、$腾讯控股(00700)$ 皆上杨。 美股纳斯达克指数与标普500指数均录的连续四个交易日上涨，因好于预期的业绩和经济数据缓解了对经济前景的担忧。科技股$特斯拉(TSLA)$ 、$微软(MSFT)$ $苹果(AAPL)$ 纷纷冲击新高，中概股","images":[{"img":"https://static.tigerbbs.com/56d1d61084247d955b3196f8e9717aa0","width":"1784","height":"1088"},{"img":"https://static.tigerbbs.com/42eafb9578606069d6fbd6d02894dae5","width":"1000","height":"1000"},{"img":"https://static.tigerbbs.com/6f30f55876f2beb2be0d910d8b0f5ab2","width":"225","height":"225"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859078451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862065262,"gmtCreate":1632819141223,"gmtModify":1632819141327,"author":{"id":"3576481856577453","authorId":"3576481856577453","name":"alexchew","avatar":"https://static.tigerbbs.com/62aecf340be4cde602564f80c4d7a151","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576481856577453","authorIdStr":"3576481856577453"},"themes":[],"htmlText":"Novavax will win in children market for sure","listText":"Novavax will win in children market for sure","text":"Novavax will win in children market for sure","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862065262","repostId":"1198320620","repostType":2,"repost":{"id":"1198320620","kind":"news","pubTimestamp":1632482340,"share":"https://www.laohu8.com/m/news/1198320620?lang=&edition=full","pubTime":"2021-09-24 19:19","market":"us","language":"en","title":"Novavax Is a Short-Term Trade in a Long-Term Paradigm","url":"https://stock-news.laohu8.com/highlight/detail?id=1198320620","media":"InvestorPlace","summary":"The tech underlining NVAX stock isn't fast enough to provide a first-response solution.\n\nI’ve said t","content":"<blockquote>\n <b>The tech underlining NVAX stock isn't fast enough to provide a first-response solution.</b>\n</blockquote>\n<p>I’ve said this before and I’ll say it again: without any hesitation,&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stock is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest beneficiaries of the new normal.</p>\n<p>As the&nbsp;<i><a href=\"https://laohu8.com/S/NYT\">New York Times</a></i>&nbsp;reported last year, NVAX stock was essentially “on the verge of collapse.” The underlying company had researched and developed several vaccines, only to fail clinically.</p>\n<p>This time, though, things are different. What’s usually a phrase reserved for scorn turned out to be true in a very positive framework.</p>\n<p>Thanks to a pivotal investment in Novavax by the former Trump administration, the biotechnology firm got the lifeline it desperately needed. From a share price that was flirting with the dollar menu, NVAX stock eventually soared to its current triple-digit offering.</p>\n<p>Of course, with such a dramatic turnaround, it raises the question: can those eyeballing Novavax today count on a profitable decision?</p>\n<p>Although it’s late in the game regarding the vaccination race against the novel coronavirus, NVAX stock has the right stuff to swing northbound — at least on a near-term basis.</p>\n<p>As our own Joseph Nograles stated, Novavax “scored a major victorywhen the European Union (EU)&nbsp;inked a supply contract&nbsp;with the pharmaceutical firm for up to 200 million doses.”</p>\n<p>Initially, as Nograles noted, the purchase seems a strange one.</p>\n<p>“After all, the vast majority of EU countries already have at least 60% to 70% of their populations fully vaccinated,” he wrote.</p>\n<p>However, the Europeans are thinking long term.</p>\n<p>“[T]he answer lies in the EU’s strategy to defend itself against future variants — as well as to prepare for possible booster shots,” Nograles wrote.</p>\n<p>So yes, Novavax has upside potential but for how long?</p>\n<p><b>Long-Term Dynamics Don’t Support NVAX Stock</b></p>\n<p>Per my colleague’s analysis, the EU is implementing a cohesive, broad-based strategy.</p>\n<p>“Novavax’s vaccine is unique in that it uses alternative technology to what’s currently in the market. Rather than being mRNA-based, it’s a&nbsp;subunit protein vaccine. As such, it’s similar to an mRNA-based shot, but a key difference is that its coronavirus spike protein is already part of the dose. Plus, Novavax’s vaccine has an adjuvant made from tree bark that helps improve a patient’s immune response.”</p>\n<p>While the subunit approach (which is a proven one used todevelop the hepatis B vaccine) is an attractive case for NVAX stock, it has certain weaknesses.</p>\n<p>Yes, the established track record will help ease concerns for those who are on the fence regarding inoculation against Covid-19. But at the same time, subunits are more expensive and possibly more time-intensive to develop.</p>\n<p>According to information from Gavi.org, subunit vaccines use living bacteria, yeast and other living organisms that need more time and specific conditions do grow. This makes themmore expensive.</p>\n<p>Further, the complexity behind subunit vaccines may have contributed to Novavax’s solution falling behind its rivals, mainly<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>&nbsp;(NYSE:<b><u>PFE</u></b>)and<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>), which used the mRNA approach.</p>\n<p>Again, in the near term, NVAX stock offers a strong narrative, but on a longer-term basis, the subunit may prove less effective.</p>\n<p>As an article on Statnews.com declared, weneed to start preparing now for the next pandemic. Even then, there’s not a whole lot that can be done about virus outbreaks given our globalized transportation networks. Therefore, a quick, efficient response — as in mRNA vaccines — is key.</p>\n<p><b>Being Realistic About the Circumstances</b></p>\n<p>I sincerely hope that no one interprets the above as me being negative toward NVAX stock. Last year, I was very hopeful that Novavax would be the first one across the clinical finish line. Again, as a proven platform, a subunit-based Covid-19 vaccine offers massive potential.</p>\n<p>However, it wasn’t to be. The superior manufacturing profile of mRNA vaccines won out.</p>\n<p>While subunits may prove to be more effective over the long haul, the Covid pandemic proved that response speed is the priority. Like it or not, that favors nucleic-acid-based approaches.</p>\n<p>That’s not to say that NVAX stock is due for the dumpsters. In the short run, there could be some upside here. However, I wouldn’t bet the house on Novavax unless the underlying science and economics of scaled-up production somehow changes.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Is a Short-Term Trade in a Long-Term Paradigm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Is a Short-Term Trade in a Long-Term Paradigm\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 19:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/nvax-stock-short-term-trade-in-long-term-paradigm/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The tech underlining NVAX stock isn't fast enough to provide a first-response solution.\n\nI’ve said this before and I’ll say it again: without any hesitation, Novavax stock is one of the biggest ...</p>\n\n<a href=\"https://investorplace.com/2021/09/nvax-stock-short-term-trade-in-long-term-paradigm/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/09/nvax-stock-short-term-trade-in-long-term-paradigm/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198320620","content_text":"The tech underlining NVAX stock isn't fast enough to provide a first-response solution.\n\nI’ve said this before and I’ll say it again: without any hesitation, Novavax stock is one of the biggest beneficiaries of the new normal.\nAs the New York Times reported last year, NVAX stock was essentially “on the verge of collapse.” The underlying company had researched and developed several vaccines, only to fail clinically.\nThis time, though, things are different. What’s usually a phrase reserved for scorn turned out to be true in a very positive framework.\nThanks to a pivotal investment in Novavax by the former Trump administration, the biotechnology firm got the lifeline it desperately needed. From a share price that was flirting with the dollar menu, NVAX stock eventually soared to its current triple-digit offering.\nOf course, with such a dramatic turnaround, it raises the question: can those eyeballing Novavax today count on a profitable decision?\nAlthough it’s late in the game regarding the vaccination race against the novel coronavirus, NVAX stock has the right stuff to swing northbound — at least on a near-term basis.\nAs our own Joseph Nograles stated, Novavax “scored a major victorywhen the European Union (EU) inked a supply contract with the pharmaceutical firm for up to 200 million doses.”\nInitially, as Nograles noted, the purchase seems a strange one.\n“After all, the vast majority of EU countries already have at least 60% to 70% of their populations fully vaccinated,” he wrote.\nHowever, the Europeans are thinking long term.\n“[T]he answer lies in the EU’s strategy to defend itself against future variants — as well as to prepare for possible booster shots,” Nograles wrote.\nSo yes, Novavax has upside potential but for how long?\nLong-Term Dynamics Don’t Support NVAX Stock\nPer my colleague’s analysis, the EU is implementing a cohesive, broad-based strategy.\n“Novavax’s vaccine is unique in that it uses alternative technology to what’s currently in the market. Rather than being mRNA-based, it’s a subunit protein vaccine. As such, it’s similar to an mRNA-based shot, but a key difference is that its coronavirus spike protein is already part of the dose. Plus, Novavax’s vaccine has an adjuvant made from tree bark that helps improve a patient’s immune response.”\nWhile the subunit approach (which is a proven one used todevelop the hepatis B vaccine) is an attractive case for NVAX stock, it has certain weaknesses.\nYes, the established track record will help ease concerns for those who are on the fence regarding inoculation against Covid-19. But at the same time, subunits are more expensive and possibly more time-intensive to develop.\nAccording to information from Gavi.org, subunit vaccines use living bacteria, yeast and other living organisms that need more time and specific conditions do grow. This makes themmore expensive.\nFurther, the complexity behind subunit vaccines may have contributed to Novavax’s solution falling behind its rivals, mainlyPfizer (NYSE:PFE)andModerna(NASDAQ:MRNA), which used the mRNA approach.\nAgain, in the near term, NVAX stock offers a strong narrative, but on a longer-term basis, the subunit may prove less effective.\nAs an article on Statnews.com declared, weneed to start preparing now for the next pandemic. Even then, there’s not a whole lot that can be done about virus outbreaks given our globalized transportation networks. Therefore, a quick, efficient response — as in mRNA vaccines — is key.\nBeing Realistic About the Circumstances\nI sincerely hope that no one interprets the above as me being negative toward NVAX stock. Last year, I was very hopeful that Novavax would be the first one across the clinical finish line. Again, as a proven platform, a subunit-based Covid-19 vaccine offers massive potential.\nHowever, it wasn’t to be. The superior manufacturing profile of mRNA vaccines won out.\nWhile subunits may prove to be more effective over the long haul, the Covid pandemic proved that response speed is the priority. Like it or not, that favors nucleic-acid-based approaches.\nThat’s not to say that NVAX stock is due for the dumpsters. In the short run, there could be some upside here. However, I wouldn’t bet the house on Novavax unless the underlying science and economics of scaled-up production somehow changes.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}